Cardiff Oncology reports Phase 2 mCRC data: ORR 72.2% vs 43.2% SoC, PFS HR 0.37; plans registrational program

Cardiff Oncology, Inc.

Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.
Plans to advance 30 mg dose into registrational program; detailed data and FDA discussions expected H1 2026.
Cash $58.3M as of Dec 31, 2025; funds operations into Q1 2027. Total op ex $49.6M, slight increase from $49.3M in 2024.
Executive changes: Mani Mohindru appointed interim CEO; Brigitte Lindsay promoted to CAO; search for permanent CEO/CFO ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.